AbbVie reported that its dual-acting bispecific antibody etentamig met a Phase 3 primary goal in relapsed or refractory multiple myeloma, improving outcomes versus standard therapy. In the study, etentamig reduced the risk of disease progression or death by 60% compared with the control arm, alongside improvements in response and progression-free survival. AbbVie also highlighted a potentially improved safety profile, with lower rates of serious immune-related adverse events associated with cytokine release syndrome and ICANS than seen with some comparable bispecifics. The company positioned the tolerability signal as a way to expand practical use beyond specialized centers. The program includes 421 trial participants and was unblinded after independent trial monitors detected a statistically significant difference at a planned interim checkpoint, with 393 evaluable patients analyzed at a mean follow-up of about 11 months.